Advancing the Fight Against Lung Cancer: Promising Breakthroughs in Targeted Therapies

In the relentless pursuit to conquer lung cancer, global pharmaceutical companies are dedicated to developing the fourth-generation EGFR inhibitors. Although no fourth-generation EGFR inhibitor has been approved for market release worldwide, several clinical trials are underway, with one notable contender being BLU-945.

1. BLU-945: Revolutionizing EGFR Inhibition
BLU-945, an orally administered and highly selective fourth-generation EGFR inhibitor developed by Blueprint, effectively targets L858R or exon 19 deletion mutations, T790M mutations, and C797S mutations while demonstrating selectivity towards wild-type EGFR and kinase groups. Encouraging results from the pivotal Phase I/II SYMPHONY clinical trial were presented at this year's ASCO conference.

2. Enhanced Efficacy in EGFR Mutant Tumors
Compared to the use of osimertinib alone, BLU-945 monotherapy or in combination with osimertinib demonstrated increased suppression of EGFR mutant tumors. As BLU-945 dosage escalated, tumor volume reduction was observed, with four patients achieving partial response upon the BLU-945 and osimertinib combination therapy.

3. Unleashing the Potential of KRAS Inhibition
KRAS mutations, including G12C, G12V, G12D, and G12R, are prevalent in lung cancer, driving approximately 32% of LUAD, 86% of PDAC, and 41% of CRC cases. While Sotorasib and Adagrasib are the approved KRASG12C inhibitors available globally, many other KRAS inhibitors, including KRASG12C, G12V, G12D, and pan-KRAS inhibitors, are being investigated in clinical settings.

4. Divarasib: A Bright Prospect for KRASG12C Inhibition
Among the investigational KRASG12C inhibitors, Divarasib by Roche has demonstrated exceptional performance. As a monotherapy for NSCLC, Divarasib achieved an objective response rate (ORR) of 53.4% and a median progression-free survival (PFS) of 13.1 months. The combination of Divarasib and cetuximab exhibited an ORR of 62.5% in Phase Ib trials for KRASG12C-mutated metastatic colorectal cancer.

5. BL-B01D1: A Dual-Target ADC for EGFR×HER3
The recent high-profile international transaction involving BL-B01D1, a dual-target ADC (antibody-drug conjugate) for EGFR×HER3, has garnered significant attention. Currently undergoing a global multicenter Phase I clinical study, BL-B01D1 aims to evaluate its safety and efficacy in patients with metastatic or unresectable NSCLC. With HER3 expressed in approximately 83% of primary NSCLC tumors, including EGFR-mutated tumors, HER3 targeting has been associated with advanced disease, shortened metastasis time, and reduced survival rates.

6. Patritumabderuxtecan: Unleashing the Potential of HER3 Inhibition
Patritumabderuxtecan, a HER3 ADC drug by Daiichi Sankyo, demonstrates significant potential. In the Phase II HERTHENA-Lung01 study presented at the WCLC conference, Patritumabderuxtecan exhibited positive results in treating previously treated EGFR-mutated NSCLC patients. Key findings included a confirmed objective response rate (cORR) of 28.4%, a median duration of response (DoR) of 6.0 months, a median PFS of 5.5 months, and a median overall survival (OS) of 11.9 months. In patients without baseline brain metastases (n=30), CNSORR confirmed by BICR per CNSRECIST was 36.7% (95% CI, 19.9%-56.1%; with 10/30 achieving complete response and 1/30 achieving partial response).

With groundbreaking advancements in targeted therapies, such as BLU-945, Divarasib, BL-B01D1, and Patritumabderuxtecan, the battle against lung cancer is gaining momentum. These innovative treatments hold the promise of improved outcomes and represent significant strides towards a brighter future for patients worldwide.